The Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145
Kancera reports that patient enrollment to the FRACTAL-study is completed and that top line results will be presented in Q3 2023
Interim Report Fourth Quarter 2022 January 1 – December 31 2022 Kancera AB (publ.), org.nr. 556806-8851
Kancera reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study and that Dr. Hanjing Xie has been appointed to Chief Medical Officer
Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology
Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies
